Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker (dihydropyridine) presented as an oral formulation for oral use. It is employed to prevent and treat cerebral vasospasm that can occur after subarachnoid hemorrhage, helping to maintain adequate cerebral blood flow.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Our global logistics network ensures timely delivery to authorized healthcare facilities across multiple continents.

Nimodipine acts on cerebral vessels to prevent and treat vasospasm associated with subarachnoid hemorrhage.

- Subarachnoid hemorrhage: prevents cerebral vasospasm, reducing risk of delayed ischemic neurological deficits. - Cerebral vasospasm: induces vasodilation to improve cerebral blood flow during the acute post‑hemorrhage period. - Delayed ischemic neurological deficit: lowers incidence by maintaining perfusion after aneurysmal bleed.

Nimodipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Nausea: occasional upset stomach. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure drop. - Myocardial infarction: rare heart attack. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Nimodipine, clinicians should observe several precautionary measures to ensure safe use.

- Monitor blood pressure: check for hypotension especially after the first doses. - Adjust in hepatic impairment: reduce dose or increase monitoring in patients with liver dysfunction. - Caution with concurrent vasodilators: risk of additive blood pressure lowering. - Avoid abrupt discontinuation: taper if long‑term therapy is stopped to prevent rebound vasospasm. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Store at room temperature: keep in original container, protect from moisture and light.

Nimodipine can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase plasma concentrations, risk of toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce drug levels, loss of efficacy. - Concurrent use with other potent vasodilators: may cause severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia caused by hypotension. - Diuretics: additive blood pressure‑lowering effect. - Other antihypertensives: may require dose adjustment. - Calcium supplements: could affect absorption, monitor therapeutic response.